Management of Disordered Puberty

Brook's Clinical Pediatric Endocrinology: Sixth Edition

Volumn , Issue , 2010, Pages 239-249

  Mieszczak, Jakub ^a   Houk, Christopher P ^b   Lee, Peter A ^a,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Central precocious puberty (CPP); Dehydroepiandrosterone sulfate (DHEAS); Disordered puberty management; Familial male limited precocious puberty (FMPP) results; Hypothalamo pituitary gonadal (HPG) axis; Ovarian hyperandrogenism presenting with hirsutism and oligomenorrhea; Peripheral precocious puberty (PPP); Pharmacologic therapy for pubertal gynecomastia; Premature pubarche from premature adrenarche

Indexed keywords

EID: 84886016036     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444316728.ch11     Document Type: Chapter

References (50)

1. Kaplowitz P. Pubertal development in girls: secular trends. Curr Opin Obstet Gynecol 2006; 18: 487-491.
2. Palmert MR, Malin HV, Boepple PA. Unsustained or slowly progressive puberty in young girls: initial presentation and long-term followup of 20 untreated patients. J Clin Endocrinol Metab 1999; 84: 415-423.
3. Klein KO. Precocious puberty: Who has it? Who should be treated? J Clin Endocrinol Metab 1999; 84: 411-414.
4. Antoniazzi F, Zamboni G. Central precocious puberty: current treatment options. Paediatr Drugs 2004; 6: 211-231.
5. Adan L, Chemaitilly W, Trivin C, Brauner R. Factors predicting adult height in girls with idiopathic central precocious puberty: implications for treatment. Clin Endocrinol (Oxf) 2002; 56: 297-302.
6. Eugster EA, Clarke W, Kletter GB, Lee PA, Neely EK, Reiter EO, et al. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. J Clin Endocrinol Metab 2007; 92: 1697-1704.
7. Hirsch HJ, Gillis D, Strich D, Chertin B, Farkas A, Lindenberg T, et al. The histrelin implant: a novel treatment for central precocious puberty. Pediatrics 2005; 116: e798-802.
8. Carel JC, Blumberg J, Seymour C, Adamsbaum C, Lahlou N. Threemonth sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty. Eur J Endocrinol 2006; 154: 119-124.
9. Roger M, Chaussain JL, Berlier P, Bost M, Canlorbe P, Colle M, et al. Long-term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6- luteinizing hormone-releasing hormone microcapsules. J Clin Endocrinol Metab 1986; 62: 670-677.
10. Trueman JA, Tillmann V, Cusick CF, Foster P, Patel L, Hall CM, et al. Suppression of puberty with long-acting goserelin (Zoladex- LA): effect on gonadotrophin response to GnRH in the first treatment cycle. Clin Endocrinol (Oxf) 2002; 57: 223-230.
11. Badaru A, Wilson DM, Bachrach LK, Fechner P, Gandrud LM, Durham E, et al. Sequential comparisons of one-month and threemonth depot leuprolide regimens in central precocious puberty. J Clin Endocrinol Metab 2006; 91: 1862-1867.
12. Bhatia S, Neely EK, Wilson DM. Serum luteinizing hormone rises within minutes after depot leuprolide injection: implications for monitoring therapy. Pediatrics 2002; 109: E30.
13. Arrigo T, De Luca F, Antoniazzi F, Galluzzi F, Segni M, Rosano M, et al. Reduction of baseline body mass index under gonadotropinsuppressive therapy in girls with idiopathic precocious puberty. Eur J Endocrinol 2004; 150: 533-537.
14. Palmert MR, Mansfield MJ, Crowley WF Jr, Crigler JF Jr, Crawford JD, Boepple PA. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty. J Clin Endocrinol Metab 1999; 84: 4480-4488.
15. Tanaka T, Niimi H, Matsuo N, Fujieda K, Tachibana K, Ohyama K, et al. Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate: evaluation of effectiveness of treatment and recovery of gonadal function. The TAP-144-SR Japanese Study Group on Central Precocious Puberty. J Clin Endocrinol Metab 2005; 90: 1371-1376.
16. Antoniazzi F, Arrigo T, Cisternino M, Galluzzi F, Bertelloni S, Pasquino AM, et al. End results in central precocious puberty with GnRH analog treatment: the data of the Italian Study Group for Physiopathology of Puberty. J Pediatr Endocrinol Metab 2000; 13 (Suppl 1): 773-780.
17. Bertelloni S, Baroncelli GI, Sorrentino MC, Perri G, Saggese G. Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females. Eur J Pediatr 1998; 157: 363-367.
18. Antoniazzi F, Zamboni G, Bertoldo F, Lauriola S, Mengarda F, Pietrobelli A, et al. Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation. J Clin Endocrinol Metab 2003; 88: 1096-1101.
19. Heger S, Muller M, Ranke M, Schwarz HP, Waldhauser F, Partsch CJ, et al. Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function. Mol Cell Endocrinol 2006; 254-255: 217-220.
20. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991; 325: 1688-1695.
21. Albright F, Butler A, Hampton A, Smith P. Syndrome characterized by osteitis fibrosa disseminate, areas of pigmentation and endocrine dysfunction, with precocious puberty in females. N Engl J Med 1937: 216: 727-746.
22. Lee PA. Medroxyprogesterone therapy for sexual precocity in girls. Am J Dis Child 1981; 135: 443-445.
23. Syed FA, Chalew SA. Ketoconazole treatment of gonadotropin independent precocious puberty in girls with McCune-Albright syndrome: a preliminary report. J Pediatr Endocrinol Metab 1999; 12: 81-83.
24. Janssen PA, Symoens JE. Hepatic reactions during ketoconazole treatment. Am J Med 1983; 74: 80-85.
25. Feuillan PP, Foster CM, Pescovitz OH, Hench KD, Shawker T, Dwyer A, et al. Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone. N Engl J Med 1986; 315: 1115-1119.
26. Feuillan PP, Jones J, Cutler GB Jr. Long-term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab 1993; 77: 647-651.
27. Nunez SB, Calis K, Cutler GB Jr, Jones J, Feuillan PP. Lack of efficacy of fadrozole in treating precocious puberty in girls with the McCune- Albright syndrome. J Clin Endocrinol Metab 2003; 88: 5730-5733.
28. Feuillan P, Calis K, Hill S, Shawker T, Robey PG, Collins MT. Letrozole treatment of precocious puberty in girls with the McCune- Albright syndrome: a pilot study. J Clin Endocrinol Metab 2007; 92: 2100-2106.
29. Mieszczak J, Lowe ES, Plourde P, Eugster EA. The aromatase inhibitor anastrozole is ineffective in the treatment of precocious puberty in girls with McCune-Albright syndrome. J Clin Endocrinol Metab 2008; 93: 2751-2754.
30. Eugster EA, Shankar R, Feezle LK, Pescovitz OH. Tamoxifen treatment of progressive precocious puberty in a patient with McCune- Albright syndrome. J Pediatr Endocrinol Metab 1999; 12: 681-686.
31. Eugster EA, Rubin SD, Reiter EO, Plourde P, Jou HC, Pescovitz OH. Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial. J Pediatr 2003; 143: 60-66.
32. Gesmundo R, Guana R, Valfre L, De Sanctis L, Matarazzo P, Marzari D, et al. Laparoscopic management of ovarian cysts in peripheral precocious puberty of McCune-Albright syndrome. J Pediatr Endocrinol Metab 2006; 19 (Suppl 2): 571-575.
33. Lee PA, Van Dop C, Migeon CJ. McCune-Albright syndrome: longterm follow-up. JAMA 1986; 256: 2980-2984.
34. Schmidt H, Kiess W. Secondary central precocious puberty in a girl with McCune-Albright syndrome responds to treatment with GnRH analogue. J Pediatr Endocrinol Metab 1998; 11: 77-81.
35. Wasniewska M, Matarazzo P, Weber G, Russo G, Zampolli M, Salzano G, et al. Clinical presentation of McCune-Albright syndrome in males. J Pediatr Endocrinol Metab 2006; 19 (Suppl 2): 619- 622.
36. Feuillan P, Merke D, Leschek EW, Cutler GB Jr. Use of aromatase inhibitors in precocious puberty. Endocr Relat Cancer 1999; 6: 303-306.
37. Laue L, Kenigsberg D, Pescovitz OH, Hench KD, Barnes KM, Loriaux DL, et al. Treatment of familial male precocious puberty with spironolactone and testolactone. N Engl J Med 1989; 320: 496-502.
38. Laue L, Jones J, Barnes KM, Cutler GB Jr. Treatment of familial male precocious puberty with spironolactone, testolactone and deslorelin. J Clin Endocrinol Metab 1993; 76: 151-155.
39. Kreher NC, Pescovitz OH, Delameter P, Tiulpakov A, Hochberg Z. Treatment of familial male-limited precocious puberty with bicalutamide and anastrozole. J Pediatr 2006; 149: 416-420.
40. Richter-Unruh A, Wessels HT, Menken U, Bergmann M, Schmittmann-Ohters K, Schaper J, et al. Male LH-independent sexual precocity in a 3.5-year-old boy caused by a somatic activating mutation of the LH receptor in a Leydig cell tumor. J Clin Endocrinol Metab 2002; 87: 1052-1056.
41. Sedlmeyer IL, Palmert MR. Delayed puberty: analysis of a large case series from an academic center. J Clin Endocrinol Metab 2002; 87: 1613-1620.
42. Raivio T, Falardeau J, Dwyer A, Quinton R, Hayes FJ, Hughes VA, et al. Reversal of idiopathic hypogonadotropic hypogonadism. N Engl J Med 2007; 357: 863-873.
43. Hero M, Wickman S, Dunkel L. Treatment with the aromatase inhibitor letrozole during adolescence increases near-final height in boys with constitutional delay of puberty. Clin Endocrinol (Oxf) 2006; 64: 510-513.
44. Dunkel L. Use of aromatase inhibitors to increase final height. Mol Cell Endocrinol 2006; 254-255: 207-216.
45. Rosenfield RL, Devine N, Hunold JJ, Mauras N, Moshang T Jr, Root AW. Salutary effects of combining early very low-dose systemic estradiol with growth hormone therapy in girls with Turner syndrome. J Clin Endocrinol Metab 2005; 90: 6424-6430.
46. Davenport ML. Evidence for early initiation of growth hormone and transdermal estradiol therapies in girls with Turner syndrome. Growth Horm IGF Res 2006; 16 (Suppl A): S91-97.
47. Riepe FG, Baus I, Wiest S, Krone N, Sippell WG, Partsch CJ. Treatment of pubertal gynecomastia with the specific aromatase inhibitor anastrozole. Horm Res 2004; 62: 113-118.
48. Plourde PV, Reiter EO, Jou HC, Desrochers PE, Rubin SD, Bercu BB, et al. Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2004; 89: 4428-4433.
49. Lahlou N, Carel JC, Chaussain JL, Roger M. Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab 2000; 13 (Suppl 1): 723-737.
50. Partsch CJ, Sippell WG. Treatment of central precocious puberty. Best Pract Res Clin Endocrinol Metab 2002; 16: 165-189.